The FIREFLY-1 Trial

FIREFLY-1 is a phase 2, multicenter, open-label study to evaluate the safety and efficacy of an investigational, oral, pan-RAF inhibitor tovorafenib in pediatric patients with RAF-altered, recurrent or progressive low-grade glioma and advanced solid tumors

Sponsor: Day One Biopharmaceuticals, Inc.

Collaborator: Pacific Pediatric Neuro-Oncology Consortium (PNOC)

Status: Currently enrolling patients

Condition: Low-grade glioma and advanced solid tumors harboring RAF alterations

Phase: 2

NCT Number: NCT04775485

EudraCT Number: 2020-003657-30

Other Study ID Numbers: PNOC026

Discover more details and enrollment information about FIREFLY-1

VIEW FIREFLY-1 TRIAL

Read a plain language summary (PLS) of the recent clinical trial results from this study

Click to view

Read a PLS of the recent clinical trial results from this study on reversible decreases in growth rate

Click to view

FIREFLY-1 Trial Sites

Trial sites are currently active in the following locations

View Trial Locations

Interested in learning more?

For clinical trial information, please email [email protected]
For medical inquiries in the US, please email [email protected]